WO2003048198A3 - Polypeptides induisant l'apoptose, polynucleotides les codant et leurs applications therapeutiques - Google Patents

Polypeptides induisant l'apoptose, polynucleotides les codant et leurs applications therapeutiques Download PDF

Info

Publication number
WO2003048198A3
WO2003048198A3 PCT/FR2002/004211 FR0204211W WO03048198A3 WO 2003048198 A3 WO2003048198 A3 WO 2003048198A3 FR 0204211 W FR0204211 W FR 0204211W WO 03048198 A3 WO03048198 A3 WO 03048198A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides encoding
therapeutic uses
inducing apoptosis
polypeptides
polypeptides inducing
Prior art date
Application number
PCT/FR2002/004211
Other languages
English (en)
Other versions
WO2003048198A2 (fr
Inventor
Monique Lafon
Christophe Prehaud
Stephanie Lay
Mireille Lafage
Maria-Isabel Thoulouze
Original Assignee
Pasteur Institut
Monique Lafon
Christophe Prehaud
Stephanie Lay
Mireille Lafage
Maria-Isabel Thoulouze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Monique Lafon, Christophe Prehaud, Stephanie Lay, Mireille Lafage, Maria-Isabel Thoulouze filed Critical Pasteur Institut
Priority to AU2002364431A priority Critical patent/AU2002364431A1/en
Publication of WO2003048198A2 publication Critical patent/WO2003048198A2/fr
Publication of WO2003048198A3 publication Critical patent/WO2003048198A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte à un polypeptide isolé ou purifié et au polynucléotide le codant induisant, par le biais de l'activation de la caspase 8 initiatrice, la formation de corps apoptotiques capables de stimuler dans un vertébré une réponse immunitaire humorale et préférentiellement, une réponse immunitaire humorale de type B dépendante.
PCT/FR2002/004211 2001-12-07 2002-12-06 Polypeptides induisant l'apoptose, polynucleotides les codant et leurs applications therapeutiques WO2003048198A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002364431A AU2002364431A1 (en) 2001-12-07 2002-12-06 Polypeptides inducing apoptosis, polynucleotides encoding them and therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,364,150 2001-12-07
CA002364150A CA2364150A1 (fr) 2001-12-07 2001-12-07 Polypeptides induisant l'apoptose, polynucleotides les codant et leurs applications therapeuthiques

Publications (2)

Publication Number Publication Date
WO2003048198A2 WO2003048198A2 (fr) 2003-06-12
WO2003048198A3 true WO2003048198A3 (fr) 2004-04-22

Family

ID=4170716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/004211 WO2003048198A2 (fr) 2001-12-07 2002-12-06 Polypeptides induisant l'apoptose, polynucleotides les codant et leurs applications therapeutiques

Country Status (3)

Country Link
AU (1) AU2002364431A1 (fr)
CA (1) CA2364150A1 (fr)
WO (1) WO2003048198A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2239330A1 (fr) * 2009-04-07 2010-10-13 Institut Pasteur Génération, régénération et protection de neurones
EP2581384A1 (fr) 2011-10-11 2013-04-17 Institut Pasteur Produits utiles pour le traitement des tumeurs malignes du système nerveux humain
EP2592091B1 (fr) 2011-11-08 2017-09-20 Institut Pasteur Polypeptides à affinité MAST2 élevée et utilisations associées

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162757A1 (fr) * 1984-04-25 1985-11-27 Transgene S.A. Vaccin contre la rage et procédé pour sa préparation
WO1989000861A1 (fr) * 1987-07-30 1989-02-09 The Wistar Institute Vaccination contre des virus apparentes a la rage
WO1997012981A1 (fr) * 1995-10-05 1997-04-10 Microbix Biosystems Inc. Adenovirus recombine de la rage
WO2001070932A2 (fr) * 2000-03-23 2001-09-27 Thomas Jefferson University Vaccin recombine contre la rage genetiquement modifie pour l'immunisation de chiens errants et de la faune

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162757A1 (fr) * 1984-04-25 1985-11-27 Transgene S.A. Vaccin contre la rage et procédé pour sa préparation
WO1989000861A1 (fr) * 1987-07-30 1989-02-09 The Wistar Institute Vaccination contre des virus apparentes a la rage
WO1997012981A1 (fr) * 1995-10-05 1997-04-10 Microbix Biosystems Inc. Adenovirus recombine de la rage
WO2001070932A2 (fr) * 2000-03-23 2001-09-27 Thomas Jefferson University Vaccin recombine contre la rage genetiquement modifie pour l'immunisation de chiens errants et de la faune

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FODOR I ET AL: "Nucleotide and deduced amino acid sequences of the glycoprotein gene of rabies virus vaccine strain Vnukovo-32.", ARCHIVES OF VIROLOGY, vol. 135, no. 3-4, 1994, pages 451 - 459, XP009009912, ISSN: 0304-8608 *
MORIMOTO KINJIRO ET AL: "Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures.", JOURNAL OF VIROLOGY, vol. 73, no. 1, January 1999 (1999-01-01), pages 510 - 518, XP002239719, ISSN: 0022-538X *
THOULOUZE MARIA-ISABEL ET AL: "Rabies virus infects mouse and human lymphocytes and induces apoptosis.", JOURNAL OF VIROLOGY, vol. 71, no. 10, 1997, pages 7372 - 7380, XP002239720, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2003048198A2 (fr) 2003-06-12
CA2364150A1 (fr) 2003-06-07
AU2002364431A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003048198A3 (fr) Polypeptides induisant l'apoptose, polynucleotides les codant et leurs applications therapeutiques
AU2001280608A1 (en) Human polynucleotides and polypeptides encoded thereby
AU8833901A (en) Novel human proteases and polynucleotides encoding the same
WO2002046426A3 (fr) Enzymes metabolisant le medicament
WO2002097039A3 (fr) Nouvelles hydroxylases humaines et polynucleotides codant celles-ci
WO2002055685A3 (fr) Nouvelle kinase humaine et polynucleotides codant pour cette kinase
WO2001081557A3 (fr) Nouvelles proteines kinases humaines et polynucleotides les codant
WO2002066624A3 (fr) Nouvelle protease humaine et polynucleotides codant pour ladite protease
WO2001057214A3 (fr) Nouvelles proteines transporteuses humaines et polynucleotides codant pour ces proteines
WO2001053493A3 (fr) Nouvelle proteine kinase humaine et polynucleotides codant pour cette proteine
WO2002059325A3 (fr) Nouvelles kinases humaines et polynucleotides codant ces kinases
WO2002031129A3 (fr) Nouvelles kinases humaines et polynucleotides codant pour ces dernieres
WO2002090517A3 (fr) Nouvelles kinases humaines et polynucleotides les codant
WO2002074932A3 (fr) Nouvelle kinase humaine et polynucleotides codant celle-ci
WO2001070806A3 (fr) Nouvelles proteines humaines secretees et polynucleotides codant lesdites proteines
ZA200005703B (en) IL-17 homologous polypeptides and therapeutic uses thereof.
WO2001094583A3 (fr) Nouvelles proteines de transport humaines et polynucleotides les codant
WO2001090179A3 (fr) Proteines ressemblant a la thrombospondine humaine et polynucleotides les codant
WO2002029026A3 (fr) Proteases humaines et polynucleotides codant pour ces proteases
WO2002072603A3 (fr) Nouvelles proteines dectine humaines et polynucleotides les codant
WO2002026949A3 (fr) Nouvelles proteases humaines et polynucleotides les codant
AU2001239378A1 (en) Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
AU7229601A (en) A novel polypeptide, a human focal adhesion kinase (fak) 13 and the polynucleotide encoding the polypeptide
AU7101700A (en) Human calcium dependent proteases and polynucleotides encoding the same
WO2002072774A3 (fr) Nouvelles proteines transporteuses humaines et polynucleotides codant pour ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP